share_log

Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9

Moomoo 24/7 ·  Mar 19 07:09

Baird analyst Joel Beatty maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $11 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment